Capital Rx Drug Recall Report

JANUARY 2025

Welcome to the **Capital Rx Drug Recall Report**. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **1/8/2025****

Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
1/1/2025	Class 2	Chlorpromazine Hcl 25 Mg Tablets	Glenmark Pharmaceuticals Inc., USA	68462-0862-01	17230133, EXP 12/31/2024	Deviations from the Current Good Manufacturing Practices (CGMP). An impurity called N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) was higher than the acceptable limit.

Capital Rx Drug Recall Report

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
1/1/2025	Class 2	Duloxetine Hcl 30 Mg Delayed-Release Capsules	Breckenridge Pharmaceutical, Inc.	51991-0747-90	222205C, EXP 11/2025	Deviations from the Current Good Manufacturing Practices (CGMP). An impurity called N-nitroso-duloxetine was higher than the acceptable limit.
1/1/2025	Class 2	Duloxetine Hcl 60 Mg Delayed-Release Capsules	(A) RemedyRepack Inc. (B) Breckenridge Pharmaceutical, Inc (C) Amerisource Health Services, LLC.	(A) 70518-0937-04, 70518-0937-03, 57237-0019-99 (B) 51991-0748-90 (C) C.1) 68001-0415-04, C.2) 68001-0415-08	(A) J0786744-061724, EXP. 06/30/2025; B3002625-060524, EXP. 10/31/2025 (B) 230077C, EXP 11/2025 (C) C.1) DT6023061B EXP 01/31/2025; C.2) DT6022166A, EXP 11/30/2024; DT6023071A, EXP 2/28/2025	Deviations from the Current Good Manufacturing Practices (CGMP). An impurity called N-nitroso-duloxetine was higher than the acceptable limit.
1/8/2025	Class 2	Levothyroxine Sodium 75 Mcg Tablets	Lupin Pharmaceuticals Inc.	68180-0967-03	LA01276, EXP 07/2026	Failing to meet impurity and degradation standards.

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Chlorpromazine Hcl 25 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211883
Class 2	Duloxetine Hcl 30 Mg Delayed-Release Capsules	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211389
Class 2	Duloxetine Hcl 60 Mg Delayed-Release Capsules	(A) https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211490 (B) https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211563 (C) C.1) https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211647 C.2) https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211648
Class 2	Levothyroxine Sodium 75 Mcg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=211499